Valneva to Present and Hold Investor Meetings at Upcoming Conferences in June

Group 1 - Valneva SE is a specialty vaccine company focused on developing, manufacturing, and commercializing prophylactic vaccines for infectious diseases, addressing unmet medical needs [4][6] - The company is advancing multiple vaccine candidates, including VLA15, the leading Lyme Disease vaccine in Phase 3 development partnered with Pfizer, and VLA1601, a second-generation Zika virus vaccine in Phase 1 clinical development [2][6] - Valneva's commercial business includes the ongoing launch of IXCHIQ®, the first and only approved chikungunya vaccine, contributing to the funding of its vaccine pipeline [2][6] Group 2 - Valneva will participate in several investor conferences in June 2024, including the Jefferies Global Healthcare Conference and the Goldman Sachs 45th Annual Global Healthcare Conference, to discuss its vaccine candidates and commercial strategies [3] - Institutional investors are invited to request one-on-one meetings with management during these conferences [3]